Journal article

Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

Wei Zhen Yeh, Putu Ayu Widyastuti, Anneke Van der Walt, Jim Stankovich, Eva Havrdova, Dana Horakova, Karolina Vodehnalova, Serkan Ozakbas, Sara Eichau, Pierre Duquette, Tomas Kalincik, Francesco Patti, Cavit Boz, Murat Terzi, Bassem Yamout, Jeannette Lechner-Scott, Patrizia Sola, Olga G Skibina, Michael Barnett, Marco Onofrj Show all



OBJECTIVE: To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. METHODS: Using data from the MSBase Registry, we included pregnancies conceived after 31 Dec 2010 from women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse, and postpartum relapse and disability progression were determined by clustered logistic regression or Cox regression analyses. RESULTS: We included 1998 pregnancies from 1619 women with MS. Preconception annualized relapse rate (ARR) was 0.29 (95% CI 0.27-0.32), fell to 0.19 (0.14-0.24) in third trimester, and increased to 0.59 (0.51-0.67) in early postpartum. Among women who used ..

View full abstract


Awarded by NHMRC of Australia

Awarded by Multiple Sclerosis Research Australia Postgraduate Scholarship

Funding Acknowledgements

Funding provided by the NHMRC of Australia, grant 1156519; Multiple Sclerosis Research Australia Postgraduate Scholarship, No. 19-0735; and Australian Government Research Training Program Scholarship. MSBase is a not-forprofit organization that receives support from Roche, Merck, Biogen, Novartis, Bayer-Schering, Sanofi Genzyme, and Teva.